XOMA-Logo-Final.png
XOMA Initiates Phase 1 European Trial in Diabetes for XOMA 052, a Novel Anti-IL-1 Antibody Designed to Target Diabetes, Rheumatoid Arthritis and Other Inflammatory Diseases
September 12, 2007 08:05 ET | XOMA Corporation
BERKELEY, Calif., Sept. 12, 2007 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) today announced the start of a second Phase 1 clinical study of XOMA 052, a potent monoclonal antibody targeting...
XOMA-Logo-Final.png
XOMA Licenses Antibody Technology to Pfizer
August 28, 2007 08:05 ET | XOMA Corporation
BERKELEY, Calif., Aug. 28, 2007 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) today announced that it has licensed to Pfizer Inc., the world's largest research-based biomedical and pharmaceutical...
XOMA-Logo-Final.png
XOMA Reports Second Quarter 2007 Financial Results
August 08, 2007 16:02 ET | XOMA Corporation
BERKELEY, Calif., Aug. 8, 2007 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, today reported financial results for the second quarter...
XOMA-Logo-Final.png
XOMA Appoints Steven B. Engle President, Chief Executive Officer and Director
August 06, 2007 08:15 ET | XOMA Corporation
BERKELEY, Calif., Aug. 6, 2007 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics for cancer and inflammatory diseases, today announced...
XOMA-Logo-Final.png
XOMA to Present At Canaccord Adams Global Growth Conference On August 9, 2007
August 02, 2007 09:00 ET | XOMA Corporation
BERKELEY, Calif., Aug. 2, 2007 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) announced today that David Boyle, XOMA's Chief Financial Officer, is scheduled to present at the Canaccord Adams Global...
XOMA-Logo-Final.png
XOMA Announces August 8 Conference Call and Webcast Discussion of Second Quarter 2007 Financial Results
August 01, 2007 09:00 ET | XOMA Corporation
BERKELEY, Calif., Aug. 1, 2007 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) will issue a news release announcing its second quarter 2007 financial results on Wednesday, August 8, 2007 after the close...
XOMA-Logo-Final.png
XOMA Elects Charles J. Fisher, M.D. to Board of Directors
July 26, 2007 08:35 ET | XOMA Corporation
BERKELEY, Calif., July 26, 2007 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) today announced the election of Charles J. Fisher, M.D. to its board of directors. Dr. Fisher will replace Arthur Kornberg,...
XOMA-Logo-Final.png
XOMA Initiates Phase I U.S. Trial in Type 2 Diabetes for XOMA 052, Monoclonal Antibody With Therapeutic Potential in Multiple Inflammatory Diseases
July 16, 2007 08:35 ET | XOMA Corporation
BERKELEY, Calif., July 16, 2007 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) today announced the initiation of Phase I clinical testing of product candidate XOMA 052, a potent monoclonal antibody...
XOMA-Logo-Final.png
XOMA Reports First Quarter 2007 Results
May 10, 2007 16:00 ET | XOMA Corporation
BERKELEY, Calif., May 10, 2007 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics for cancer and immunological disorders, today announced...
XOMA-Logo-Final.png
XOMA Executives to Present at BIO2007 Convention, Rodman & Renshaw Global Healthcare, Needham Biotechnology and Jefferies Healthcare Conferences
May 07, 2007 18:30 ET | XOMA Corporation
BERKELEY, Calif., May 7, 2007 (PRIME NEWSWIRE) -- Executives from XOMA Ltd. (Nasdaq:XOMA), a therapeutic antibody discovery and product development company, will be presenting at four upcoming...